Drug intelligence / Profile preview

paraprizumab

Development stage: Preclinical
Lead developer: MedImmune

Overview

Paraprizumab is an investigational drug currently being evaluated as a neoadjuvant therapy. It is used in combination with platinum-based dual chemotherapy for the treatment of resectable stage II-IIIA non-small cell lung cancer (NSCLC). The specific mechanism of action and modality of paraprizumab are not detailed in the provided context.

Other names: Peampriumab

Beyond the preview

Go deeper on paraprizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paraprizumab.

Explore the full profile